By Mr Arnold Reynaldi

Preprints

Kent SJ; Li S; Amarasena TH; Reynaldi A; Leeming MG; Juno JA; Wheatley AK; Deliyannis G; Godfrey DI; Nolan T; Pouton CW; Davenport MP; Ju Y, 2026, In Vivo Blood Kinetics and Transcript Integrity of Three mRNA–Lipid Nanoparticle Vaccines in Humans, http://dx.doi.org/10.64898/2026.03.13.26348310

Koutsakos M; Reynaldi A; Lee WS; Nguyen J; Amarasena T; Taiaroa G; Kinsella P; Liew KC; Tran T; Kent H; Tan H-X; Rowntree L; Nguyen T; Thomas P; Kedzierska K; Petersen J; Rossjohn J; Williamson D; Khoury D; Davenport M; Kent S; Wheatley A; Juno J, 2022, Rapid Recall and de novo T Cell Responses During SARS-CoV-2 Breakthrough Infection, http://dx.doi.org/10.2139/ssrn.4311124

Cromer D; Steain M; Reynaldi A; Schlub TE; Wheatley AK; Juno JA; Kent SJ; Triccas JA; Khoury DS; Davenport MP, 2021, SARS-CoV-2 variants: levels of neutralisation required for protective immunity, http://dx.doi.org/10.1101/2021.08.11.21261876

Juno J; Wragg K; Lee WS; Amarasena T; Reynaldi A; Koutsakos M; Konstandopoulos P; Field K; Esterbauer R; Tan H-X; Kent H; Davenport M; Wheatley A; Kent S, 2021, Tracking the kinetics and phenotype of spike epitope-specific CD4 T cell immunity in the context of SARS-CoV-2 infection and vaccination, http://dx.doi.org/10.21203/rs.3.rs-957030/v1

Khoury DS; Cromer D; Reynaldi A; Schlub TE; Wheatley AK; Juno JA; Subbarao K; Kent SJ; Triccas JA; Davenport MP, 2021, What level of neutralising antibody protects from COVID-19?, http://dx.doi.org/10.1101/2021.03.09.21252641

Kent SJ; Li S; Amarasena TH; Reynaldi A; Lee WS; Leeming MG; O’Connor DH; Nguyen J; Kent HE; Caruso F; Juno JA; Wheatley AK; Davenport MP; Ju Y, Blood Distribution of SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine in Humans, http://dx.doi.org/10.1101/2024.07.25.24311039

Lee WS; Selva KJ; Davis SK; Wines BD; Reynaldi A; Esterbauer R; Kelly HG; Haycroft ER; Tan H-X; Juno JA; Wheatley AK; Hogarth PM; Cromer D; Davenport MP; Chung AW; Kent SJ, Decay of Fc-dependent antibody functions after mild to moderate COVID-19, http://dx.doi.org/10.1101/2020.12.13.20248143

Lee WS; Tan H-X; Reynaldi A; Esterbauer R; Koutsakos M; Nguyen J; Amarasena T; Kent HE; Aggarwal A; Turville SG; Taiaroa G; Kinsella P; Liew KC; Tran T; Williamson DA; Cromer D; Davenport MP; Kent SJ; Juno JA; Khoury DS; Wheatley AK, Durable reprogramming of neutralising antibody responses following breakthrough Omicron infection, http://dx.doi.org/10.1101/2023.02.19.23286159

Koutsakos M; Lee WS; Reynaldi A; Tan H-X; Gare G; Kinsella P; Liew KC; Williamson DA; Kent HE; Stadler E; Cromer D; Khoury DS; Wheatley AK; Juno JA; Davenport MP; Kent SJ, Dynamics of immune recall following SARS-CoV-2 vaccination or breakthrough infection, http://dx.doi.org/10.1101/2021.12.23.21268285

Wheatley AK; Juno JA; Wang JJ; Selva KJ; Reynaldi A; Tan H-X; Lee WS; Wragg KM; Kelly HG; Esterbauer R; Davis SK; Kent HE; Mordant FL; Schlub TE; Gordon DL; Khoury DS; Subbarao K; Cromer D; Gordon TP; Chung AW; Davenport MP; Kent SJ, Evolution of immunity to SARS-CoV-2, http://dx.doi.org/10.1101/2020.09.09.20191205

Juno JA; Tan H-X; Lee WS; Reynaldi A; Kelly HG; Wragg K; Esterbauer R; Kent HE; Batten CJ; Mordant FL; Gherardin NA; Pymm P; Dietrich MH; Scott NE; Tham W-H; Godfrey DI; Subbarao K; Davenport MP; Kent SJ; Wheatley AK, Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19, http://dx.doi.org/10.1101/2020.05.17.20104869

Selva KJ; Ramanathan P; Haycroft ER; Reynaldi A; Cromer D; Tan CW; Wang L-F; Wines BD; Hogarth PM; Downie LE; Davis SK; Purcell RA; Kent HE; Juno JA; Wheatley AK; Davenport MP; Kent SJ; Chung AW, Lasting first impression: Pre-existing immunity restricts mucosal antibody responses during Omicron breakthrough, http://dx.doi.org/10.1101/2023.03.28.23287848

Goel RR; Painter MM; Apostolidis SA; Mathew D; Meng W; Rosenfeld AM; Lundgreen KA; Reynaldi A; Khoury DS; Pattekar A; Gouma S; Kuri-Cervantes L; Hicks P; Dysinger S; Hicks A; Sharma H; Herring S; Korte S; Baxter AE; Oldridge DA; Giles JR; Weirick ME; McAllister CM; Awofolaju M; Tanenbaum N; Drapeau EM; Dougherty J; Long S; D’Andrea K; Hamilton JT; McLaughlin M; Williams JC; Adamski S; Kuthuru O; Unit TUCP; Frank I; Betts MR; Vella LA; Grifoni A; Weiskopf D; Sette A; Hensley SE; Davenport MP; Bates P; Prak ETL; Greenplate AR; Wherry EJ, mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern, http://dx.doi.org/10.1101/2021.08.23.457229

Wagstaffe HR; Thwaites RS; Reynaldi A; Sidhu JK; McKendry R; Ascough S; Papargyris L; Collins AM; Xu J; Lemm N-M; Siggins MK; Chain BM; Killingley B; Kalinova M; Mann A; Catchpole A; Davenport MP; Openshaw PJM; Chiu C, Mucosal and Systemic Immune Correlates of Viral Control following SARS-CoV-2 Infection Challenge in Seronegative Adults, http://dx.doi.org/10.1101/2023.07.21.23292994

Cromer D; Steain M; Reynaldi A; Schlub TE; Sasson SC; Kent SJ; Khoury DS; Davenport MP, Neutralising antibodies predict protection from severe COVID-19, http://dx.doi.org/10.1101/2022.06.09.22275942

Cromer D; Reynaldi A; Hie A; Schlub TE; Juno JA; Wheatley AK; Kent SJ; Khoury DS; Davenport MP, Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates, http://dx.doi.org/10.1101/2024.02.08.24302032

Hogan AB; Mitchell A; Stadler E; Chung Y; Reynaldi A; Elias KM; Docken S; Khoury DS; Schlub T; Davenport MP; Cromer D, Quantifying the association between neutralising antibodies and protection from RSV disease in infants and adults: A systematic review and meta-analysis, http://dx.doi.org/10.64898/2026.02.13.26346212

Koutsakos M; Reynaldi A; Lee WS; Nguyen J; Amarasena T; Taiaroa G; Kinsella P; Liew KC; Tran T; Kent HE; Tan H-X; Rowntree LC; Nguyen THO; Thomas PG; Kedzierska K; Petersen J; Rossjohn J; Williamson DA; Khoury D; Davenport MP; Kent SJ; Wheatley AK; Juno JA, Rapid recall and de novo T cell responses during SARS-CoV-2 breakthrough infection, http://dx.doi.org/10.1101/2022.12.19.521129

Hilt ZT; Reynaldi A; Steinhilber M; Zhang S; Wesnak SP; Smith NL; Davenport MP; Rudd BD, Recent thymic emigrants are preferentially recruited into the memory pool during persistent infection, http://dx.doi.org/10.1101/2025.02.06.636722

Cromer D; Reynaldi A; Steain M; Triccas JA; Davenport MP; Khoury DS, Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial, http://dx.doi.org/10.1101/2021.06.29.21259504

Selva KJ; Davis SK; Haycroft ER; Lee WS; Lopez E; Reynaldi A; Davenport MP; Kent HE; Juno JA; Chung AW; Kent SJ, Tear antibodies to SARS-CoV-2: implications for transmission, http://dx.doi.org/10.1101/2021.08.02.21261479

Back to profile page